Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

M Kohno; M Perch; E Andersen; J Carlsen; C B Andersen; M Iversen

doi:10.1016/j.transproceed.2011.02.007

Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

M Kohno, M Perch, E Andersen, J Carlsen, C B Andersen, M Iversen

18 Citations (Scopus)

Abstract

A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

Original language	English
Journal	Transplantation Proceedings
Volume	43
Issue number	5
Pages (from-to)	1868-70
Number of pages	3
ISSN	0041-1345
DOIs	https://doi.org/10.1016/j.transproceed.2011.02.007
Publication status	Published - Jun 2011

Access to Document

10.1016/j.transproceed.2011.02.007

Cite this

@article{f1d969402bf3474e87cf4523575557d3,

title = "Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation",

abstract = "A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.",

author = "M Kohno and M Perch and E Andersen and J Carlsen and Andersen, {C B} and M Iversen",

year = "2011",

month = jun,

doi = "10.1016/j.transproceed.2011.02.007",

language = "English",

volume = "43",

pages = "1868--70",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

AU - Kohno, M

AU - Perch, M

AU - Andersen, E

AU - Carlsen, J

AU - Andersen, C B

AU - Iversen, M

PY - 2011/6

Y1 - 2011/6

N2 - A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

AB - A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

U2 - 10.1016/j.transproceed.2011.02.007

DO - 10.1016/j.transproceed.2011.02.007

M3 - Journal article

SN - 0041-1345

VL - 43

SP - 1868

EP - 1870

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 5

ER -

Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

Abstract

Access to Document

Fingerprint

Cite this